Meeting
2019 Gastrointestinal Cancers Symposium
Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
Authors
Emilie Wang
University of South Florida, Tampa, FL
Emilie Wang , Dae Won Kim , Amit Mahipal , Dung-Tsa Chen , Biwei Cao , Fadzai Masawi , Richard D. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02292173
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 431)
DOI
10.1200/JCO.2019.37.4_suppl.431
Abstract #
431
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
A phase Ia/Ib trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer.
First Author: Heloisa P. Soares
Poster
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
First Author: Changhoon Yoo
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer
Poster
2023 ASCO Breakthrough
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.
First Author: Gulam Abbas Manji